Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice (original) (raw)
Construction of proteolysis resistant human interleukin-2 by fusion to its protective single chain antibody
YEHEZKEL SHAMI
Cytokine, 2003
View PDFchevron_right
Interleukin 2 receptor—A target for immunosuppressive therapy
Michael Shapiro
Transplantation Reviews, 1987
View PDFchevron_right
Expression and Ligand Binding Assays of Soluble Cytokine Receptor–Immunoglobulin Fusion Proteins
huong le
Protein Expression and Purification, 1998
View PDFchevron_right
Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice
Gilles Gallant, Thi-Sau Migone
Cancer Immunology, Immunotherapy, 2005
View PDFchevron_right
The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses
Brendon Coventry
Cancer Management and Research, 2012
View PDFchevron_right
Interleukin 2-Based Fusion Proteins for the Treatment of Cancer
Alana MacDonald
Journal of Immunology Research
View PDFchevron_right
Suppression of cell-mediated and humoral immune responses by an interleukin-2-immunoglobulin fusion protein in mice
Adrian Onu
Journal of Clinical …, 1996
View PDFchevron_right
Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors
Michael Super
Cancer research, 1999
View PDFchevron_right
Bacterial overexpression of the human interleukin-2 in insoluble form via the pET Trx fusion system
sohrab boozarpour
View PDFchevron_right
Human Interleukin 2 (IL-2) Promotion of Immune Regulation and ClinicalOutcomes: A Review
Claudia Regina Bonini Domingos
Journal of Cytokine Biology, 2016
View PDFchevron_right
Immunotherapy with interleukin-2 by constant infusion with and without adoptive cell transfer and with weekly doxorubicin
Paolo Paciucci
Cancer Treatment Reviews, 1989
View PDFchevron_right
Interleukin-2 Tickles T Cell Memory
Frederick Masson
Immunity, 2010
View PDFchevron_right
An integrated strategy for the process development of a recombinant antibody-cytokine fusion protein expressed in BHK cells
Elsa Dias
Applied Microbiology and Biotechnology, 1999
View PDFchevron_right
Molecular Cloning of cDNA for the Human Interleukin-2 Receptor
Bhusana Premanode
Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, 1985
View PDFchevron_right
Clearance mechanism of a mannosylated antibody–enzyme fusion protein used in experimental cancer therapy
Mark Lowdell
Glycobiology, 2006
View PDFchevron_right
Cytokines with Possible Clinical Utility
Roland Mertelsmann
… new results in …, 1987
View PDFchevron_right
Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon α
Tilman Sauerbruch
Cancer Immunology Immunotherapy, 1993
View PDFchevron_right
Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity
Peisheng Hu
Blood, 2003
View PDFchevron_right
Evaluation of an Albumin-Binding Domain Protein Fused to Recombinant Human IL-2 and Its Effects on the Bioactivity and Serum Half-Life of the Cytokine
elham adabi
Iranian Biomedical Journal
View PDFchevron_right
Pharmacokinetics of recombinant interleukin 2 in humans
Roland Mertelsmann
Cancer research, 1990
View PDFchevron_right
Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig
Jean-Claude Becker
New England Journal of Medicine, 2003
View PDFchevron_right
Physiology and Pathology of Cytokine: Commercial Production and Medical Use
Mitar Lutovac
Physiology and Pathology of Immunology, 2017
View PDFchevron_right
An IL-7 Fusion Protein That Shows Increased Thymopoietic Ability
Dominic Wells
The Journal of Immunology, 2005
View PDFchevron_right
Cytokines and anti-cytokines as therapeutics — An update
bhupinder kalra
European Journal of Pharmacology, 2008
View PDFchevron_right
Challenges in the Pharmacokinetics of Therapeutic Proteins
Wararat Limothai
View PDFchevron_right
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
William Strohl
BioDrugs, 2015
View PDFchevron_right
Fusion partners can increase the expression of recombinant interleukins via transient transfection in 2936E cells
David Meininger
Protein Science, 2010
View PDFchevron_right
Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer
Francesco Indiveri
Cancer Immunology Immunotherapy, 1993
View PDFchevron_right
Expression and purification of recombinant swine interleukin-4
Chieko Kai
Comparative Immunology, Microbiology and Infectious Diseases, 2005
View PDFchevron_right
A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy
Circe Mesa
OncoImmunology, 2020
View PDFchevron_right
Interleukin-12 inhibits liver-specific drug-inducible systems in vivo
Mariel Zabala
2007
View PDFchevron_right
IL-2 induces in vivo suppression by CD4+CD25+Foxp3+ regulatory T cells
Alexander Scheffold
European Journal of Immunology, 2008
View PDFchevron_right
Splice isoforms of human interleukin-4 are functionally active in mice in vivo
Sergei Atamas
Immunology, 2011
View PDFchevron_right
Anti-inflammatory Disease Therapies: Challenges and Strategies in Drug Development
Joel Parry
Toxicologic Pathology, 2012
View PDFchevron_right
A Review on Therapeutic Proteins: Stability Aspects and Clinical Implications
Farah Farah
International Research Journal Of Pharmacy, 2019
View PDFchevron_right